Crossmark

Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol

Crossref DOI link: https://doi.org/10.1038/nbt.4182

Published Online: 2018-07-09

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Lili

Smith, Jeff

Breton, Camilo

Clark, Peter

Zhang, Jia

Ying, Lei

Che, Yan

Lape, Janel

Bell, Peter

Calcedo, Roberto

Buza, Elizabeth L

Saveliev, Alexei

Bartsevich, Victor V

He, Zhenning

White, John

Li, Mingyao

Jantz, Derek

Wilson, James M
License Information

Text and Data Mining valid from 2018-07-09
More Information

Article History

Received: 28 November 2017

Accepted: 5 June 2018

First Online: 9 July 2018

Competing interests

: J.M.W. is an advisor to, holds equity in, and has a sponsored research agreement with REGENXBIO; he also has a sponsored research agreement with Ultragenyx, Biogen, and Janssen, which are licensees of Penn technology. In addition, he has sponsored research agreements with Precision Biosciences and Moderna Therapeutics. J.M.W. holds equity in Solid Bio. J.M.W. and L.W. are inventors on patents that have been licensed to various biopharmaceutical companies. J.S., J.L., V.V.B., and D.J. are employees of, and hold equity in, Precision Biosciences.